1. Academic Validation
  2. IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD

IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD

  • Int J Chron Obstruct Pulmon Dis. 2022 Oct 14:17:2589-2602. doi: 10.2147/COPD.S375006.
Danyang Li 1 Tong Wang 2 Qianli Ma 3 Lu Zhou 1 Yanqing Le 1 Yafei Rao 1 Liang Jin 1 Yuqiang Pei 1 Yaning Cheng 4 Chen Huang 5 Xiaoyan Gai 1 Yongchang Sun 1
Affiliations

Affiliations

  • 1 Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
  • 2 Department of Thoracic Surgery, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
  • 3 Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, 100029, People's Republic of China.
  • 4 School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, People's Republic of China.
  • 5 Center of Basic Medical Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
Abstract

Background: It has been reported that a disintegrin and metalloproteinase 9 (ADAM9) is involved in the pathogenesis of cigarette smoke (CS)-associated chronic obstructive pulmonary disease (COPD). But how CS exposure leads to upregulation of ADAM9 remains unknown.

Methods: Patients who underwent lobectomy for a solitary pulmonary nodule were enrolled and divided into three groups: non-smokers with normal lung function, smokers without COPD and smoker patients with COPD. Immunoreactivity of interleukin (IL)-17A and ADAM9 in small airways and alveolar walls was measured by immunohistochemistry. Wild-type and Il17a -/- C57BL/6 mice were exposed to CS for six months, and ADAM9 expression in the airway epithelia was measured by immunoreactivity. In addition, the protein and mRNA expression levels of IL-17A and ADAM9 were assessed in CS extract (CSE) and/or IL-17A-treated human bronchial epithelial (HBE) cells.

Results: The immunoreactivity of ADAM9 was increased in the airway epithelia and alveolar walls of patients with COPD compared to that of the controls. The expression of IL-17A was also upregulated in airway epithelial cells of patients with COPD and correlated positively with the level of ADAM9. The results from the animal model showed that Il17a -/- mice were protected from emphysema induced by CS exposure, together with a reduced level of ADAM9 expression in the airway epithelia, suggesting a possible link between ADAM9 and IL-17A. Consistently, our in vitro cell model showed that CSE stimulated the expression of ADAM9 and IL-17A in HBE cells in a dose- and time-dependent manner. Recombinant IL-17A induced ADAM9 upregulation in HBE cells and had a synergistic effect with CSE, whereas blocking IL-17A inhibited CSE-induced ADAM9 expression. Further analysis revealed that IL-17A induced c-Jun N-terminal kinase (JNK) phosphorylation, thereby increasing ADAM9 expression.

Conclusion: Our results revealed a novel role of IL-17A in CS-related COPD, where IL-17A contributes to ADAM9 expression by activating JNK signaling.

Keywords

a disintegrin and metalloproteinase 9; airway epithelium; chronic obstructive pulmonary disease; interleukin-17A.

Figures
Products